1
|
Trusova V, Karnaukhov I, Zelinsky A, Borts B, Ushakov I, Sidenko L, Gorbenko G. Radiolabeling of bionanomaterials with technetium 99m: current state and future prospects. Nanomedicine (Lond) 2024; 19:1569-1580. [PMID: 39011593 PMCID: PMC11321418 DOI: 10.1080/17435889.2024.2368454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 06/12/2024] [Indexed: 07/17/2024] Open
Abstract
Radiolabeling of bionanomaterials with technetium-99m (99mTc) has become a promising approach in combining the benefits of nanotechnology and nuclear medicine for diagnostic and therapeutic purposes. This review is intended to provide a comprehensive overview of the state-of-the-art of radiolabeling of bionanomaterials with 99mTc, highlighting the synthesis methods, labeling mechanisms, biological evaluation, physicochemical characterization and clinical applications of 99mTc-labeled bionanomaterials. Various types of nanomaterials are considered in the review, including lipid- and protein-based nanosystems, dendrimers and polymeric nanomaterials. Moreover, the review assesses the challenges presented by this emerging field, such as stability of the radiolabel, potential toxicity of the nanomaterials and regulatory aspects. Finally, promising future perspectives and areas of research development in 99mTc-labeled bionanomaterials are discussed.
Collapse
Affiliation(s)
- Valeriya Trusova
- Department of Medical Physics & Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv61022, Ukraine
| | - Ivan Karnaukhov
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Andrey Zelinsky
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Borys Borts
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Igor Ushakov
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Larysa Sidenko
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Galyna Gorbenko
- Department of Medical Physics & Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv61022, Ukraine
| |
Collapse
|
2
|
Cleynhens J, Verbruggen A. Technetium-99m radiopharmaceuticals—Radiochemistry and radiolabeling. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00006-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Duatti A. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. Nucl Med Biol 2021; 92:202-216. [PMID: 32475681 DOI: 10.1016/j.nucmedbio.2020.05.005] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 05/07/2020] [Accepted: 05/18/2020] [Indexed: 02/06/2023]
Abstract
Rapid imaging acquisition, high spatial resolution and sensitivity, powered by advancements in solid-state detector technology, are significantly changing the perspective of single photon emission tomography (SPECT). In particular, this evolutionary step is fueling a rediscovery of technetium-99m, a still unique radionuclide within the nuclear medicine scenario because of its ideal nuclear properties and easy preparation of its radiopharmaceuticals that does not require a costly infrastructure and complex procedures. Scope of this review is to show that the arsenal of technetium-99m radiopharmaceuticals is already equipped with imaging agents that may complement and integrate the role played by analogous tracers developed for positron emission tomography (PET). These include, in particular, somatostatin (SST) and prostate-specific membrane antigen (PSMA) receptor targeting agents, and a number of peptide-derived radiopharmaceuticals. Additionally, these recent technological developments, combined with new myocardial perfusion tracers having more favorable biodistribution and pharmacokinetic properties as compared to current commercial agents, may also reinvigorate the prevailing position still hold by technetium-99m radiopharmaceuticals in nuclear cardiology.
Collapse
Affiliation(s)
- Adriano Duatti
- Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.
| |
Collapse
|
4
|
Sarcinelli MA, Albernaz MDS, Szwed M, Iscaife A, Leite KRM, Junqueira MDS, Bernardes ES, da Silva EO, Tavares MIB, Santos-Oliveira R. Nanoradiopharmaceuticals for breast cancer imaging: development, characterization, and imaging in inducted animals. Onco Targets Ther 2016; 9:5847-5854. [PMID: 27713638 PMCID: PMC5045224 DOI: 10.2147/ott.s110787] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Monoclonal antibodies as polymeric nanoparticles are quite interesting and endow this new drug category with many advantages, especially by reducing the number of adverse reactions and, in the case of radiopharmaceuticals, also reducing the amount of radiation (dose) administered to the patient. In this study, a nanoradiopharmaceutical was developed using polylactic acid (PLA)/polyvinyl alcohol (PVA)/montmorillonite (MMT)/trastuzumab nanoparticles labeled with technetium-99m (99mTc) for breast cancer imaging. In order to confirm the nanoparticle formation, atomic force microscopy and dynamic light scattering were performed. Cytotoxicity of the nanoparticle and biodistribution with 99mTc in healthy and inducted animals were also measured. The results from atomic force microscopy showed that the nanoparticles were spherical, with a size range of ~200-500 nm. The dynamic light scattering analysis demonstrated that over 90% of the nanoparticles produced had a size of 287 nm with a zeta potential of -14,6 mV. The cytotoxicity results demonstrated that the nanoparticles were capable of reaching breast cancer cells. The biodistribution data demonstrated that the PLA/PVA/MMT/trastuzumab nanoparticles labeled with 99mTc have great renal clearance and also a high uptake by the lesion, as ~45% of the PLA/PVA/MMT/trastuzumab nanoparticles injected were taken up by the lesion. The data support PLA/PVA/MMT/trastuzumab labeled with 99mTc nanoparticles as nanoradiopharmaceuticals for breast cancer imaging.
Collapse
Affiliation(s)
- Michelle Alvares Sarcinelli
- Instituto de Macromoléculas Professora Eloisa Mano Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Laboratory of Medical Investigation, Faculty of Medicine, São Paulo University, São Paulo, Brazil
| | | | - Marzena Szwed
- Department of Thermobiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Alexandre Iscaife
- Laboratory of Medical Investigation, Faculty of Medicine, São Paulo University, São Paulo, Brazil
| | | | - Mara de Souza Junqueira
- Laboratory of Experimental Oncology, Faculty of Medicine, São Paulo University, São Paulo, Brazil
| | | | - Emerson Oliveira da Silva
- Instituto de Macromoléculas Professora Eloisa Mano Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Maria Ines Bruno Tavares
- Instituto de Macromoléculas Professora Eloisa Mano Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Ralph Santos-Oliveira
- Laboratory of Nanoradiopharmaceuticals, Zona Oeste State University, Rio de Janeiro, Brazil
| |
Collapse
|
5
|
Motaleb MA, Ibrahem IT, Ayoub VR, Geneidi AS. Preparation and biological evaluation of99mTc-ropinirole as a novel radiopharmaceutical for brain imaging. J Labelled Comp Radiopharm 2016; 59:147-52. [DOI: 10.1002/jlcr.3380] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 12/17/2015] [Accepted: 01/19/2016] [Indexed: 11/08/2022]
Affiliation(s)
- M. A. Motaleb
- Hot Labs Center; Egyptian Atomic Energy Authority; Cairo Egypt
| | - I. T. Ibrahem
- Hot Labs Center; Egyptian Atomic Energy Authority; Cairo Egypt
| | - V. R. Ayoub
- Hot Labs Center; Egyptian Atomic Energy Authority; Cairo Egypt
| | - A. S. Geneidi
- Faculty of Pharmacy; Ain Shams University; Cairo Egypt
| |
Collapse
|
6
|
Jürgens S, Herrmann WA, Kühn FE. Rhenium and technetium based radiopharmaceuticals: Development and recent advances. J Organomet Chem 2014. [DOI: 10.1016/j.jorganchem.2013.07.042] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
7
|
Abstract
Technetium and Rhenium are the two lower elements in the manganese triad. Whereas rhenium is known as an important part of high resistance alloys, technetium is mostly known as a cumbersome product of nuclear fission. It is less known that its metastable isotope 99mTc is of utmost importance in nuclear medicine diagnosis. The technical application of elemental rhenium is currently complemented by investigations of its isotope 188Re , which could play a central role in the future for internal, targeted radiotherapy. This article will briefly describe the basic principles behind diagnostic methods with radionuclides for molecular imaging, review the 99mTc -based radiopharmaceuticals currently in clinical routine and focus on the chemical challenges and current developments towards improved, radiolabeled compounds for diagnosis and therapy in nuclear medicine.
Collapse
Affiliation(s)
- ROGER ALBERTO
- University of Zürich, Institute of Inorganic Chemistry, Winterthurerstr. 190, CH-8057 Zürich, Switzerland
| |
Collapse
|
8
|
Lin X, Xie J, Chen X. Protein-based tumor molecular imaging probes. Amino Acids 2011; 41:1013-36. [PMID: 20232092 PMCID: PMC3617487 DOI: 10.1007/s00726-010-0545-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2010] [Accepted: 02/24/2010] [Indexed: 12/30/2022]
Abstract
Molecular imaging is an emerging discipline which plays critical roles in diagnosis and therapeutics. It visualizes and quantifies markers that are aberrantly expressed during the disease origin and development. Protein molecules remain to be one major class of imaging probes, and the option has been widely diversified due to the recent advances in protein engineering techniques. Antibodies are part of the immunosystem which interact with target antigens with high specificity and affinity. They have long been investigated as imaging probes and were coupled with imaging motifs such as radioisotopes for that purpose. However, the relatively large size of antibodies leads to a half-life that is too long for common imaging purposes. Besides, it may also cause a poor tissue penetration rate and thus compromise some medical applications. It is under this context that various engineered protein probes, essentially antibody fragments, protein scaffolds, and natural ligands have been developed. Compared to intact antibodies, they possess more compact size, shorter clearance time, and better tumor penetration. One major challenge of using protein probes in molecular imaging is the affected biological activity resulted from random labeling. Site-specific modification, however, allows conjugation happening in a stoichiometric fashion with little perturbation of protein activity. The present review will discuss protein-based probes with focus on their application and related site-specific conjugation strategies in tumor imaging.
Collapse
Affiliation(s)
- Xin Lin
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | |
Collapse
|
9
|
Ackroyd NC, Katzenellenbogen JA. Pyridyl-Cyclopentadiene Re(CO)(2) Complexes as a Compact Core Systems for SPECT Ligand Development. Organometallics 2010; 29:3669-3671. [PMID: 20865134 PMCID: PMC2942762 DOI: 10.1021/om100521s] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An η(1) η(5)-rhenium complex has been prepared, starting from a CpRe(CO)(3) complex substituted with a pendant aromatic amine. This unique complex has potential application as a surrogate for a technetium-99m complex, a common radioisotope for biomedical imaging applications. Chelation occurred via photochemical decarbonylation of the rhenium, which opened a binding-site for the aromatic amine.
Collapse
Affiliation(s)
- Nathan C Ackroyd
- Department of Chemical and Biological Sciences, Mount Royal University, 4825 Mount Royal Gate SW, Calgary Alberta Canada T3E 6K6
| | | |
Collapse
|
10
|
Kuninobu Y, Nishina Y, Matsuki T, Takai K. Synthesis of Cp-Re complexes via olefinic C-H activation and successive formation of cyclopentadienes. J Am Chem Soc 2008; 130:14062-3. [PMID: 18826218 DOI: 10.1021/ja805921f] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Treatment of an alpha,beta-unsaturated ketimine with an alpha,beta-unsaturated carbonyl compound in the presence of a rhenium complex, Re2(CO)10, gave a cyclopentadienyl-rhenium complex. This reaction proceeds via rhenium-catalyzed C-H bond activation of an olefinic C-H bond, insertion of an alpha,beta-unsaturated carbonyl compound into a Re-C bond of the alkenylrhenium intermediate, intramolecular nucleophilic cyclization, reductive elimination, elimination of aniline to give a cyclopentadiene derivative, followed by the formation of a cyclopentadienyl-rhenium complex from the cyclopentadiene derivative and the rhenium complex.
Collapse
Affiliation(s)
- Yoichiro Kuninobu
- Division of Chemistry and Biochemistry, Graduate School of Natural Science and Technology, Okayama University, Tsushima, Okayama 700-8530, Japan.
| | | | | | | |
Collapse
|
11
|
Hong H, Sun J, Cai W. Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen. Biomark Insights 2008; 3:435-451. [PMID: 19578524 PMCID: PMC2688357 DOI: 10.4137/bmi.s1124] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Carcinoembryonic antigen (CEA), highly expressed in many cancer types, is an important target for cancer diagnosis and therapy. Radionuclide-based imaging techniques (gamma camera, single photon emission computed tomography [SPECT] and positron emission tomography [PET]) have been extensively explored for CEA-targeted cancer imaging both preclinically and clinically. Briefly, these studies can be divided into three major categories: antibody-based, antibody fragment-based and pretargeted imaging. Radiolabeled anti-CEA antibodies, reported the earliest among the three categories, typically gave suboptimal tumor contrast due to the prolonged circulation life time of intact antibodies. Subsequently, a number of engineered anti-CEA antibody fragments (e.g. Fab’, scFv, minibody, diabody and scFv-Fc) have been labeled with a variety of radioisotopes for CEA imaging, many of which have entered clinical investigation. CEA-Scan (a 99mTc-labeled anti-CEA Fab’ fragment) has already been approved by the United States Food and Drug Administration for cancer imaging. Meanwhile, pretargeting strategies have also been developed for CEA imaging which can give much better tumor contrast than the other two methods, if the system is designed properly. In this review article, we will summarize the current state-of-the-art of radionuclide-based cancer imaging targeting CEA. Generally, isotopes with short half-lives (e.g. 18F and 99mTc) are more suitable for labeling small engineered antibody fragments while the isotopes with longer half-lives (e.g. 123I and 111In) are needed for antibody labeling to match its relatively long circulation half-life. With further improvement in tumor targeting efficacy and radiolabeling strategies, novel CEA-targeted agents may play an important role in cancer patient management, paving the way to “personalized medicine”.
Collapse
Affiliation(s)
- Hao Hong
- Departments of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A
| | | | | |
Collapse
|
12
|
99mTc-labeling and in vitro characterization of N4- and N3S-RGDS-derivative peptides. J Radioanal Nucl Chem 2007. [DOI: 10.1007/s10967-007-6867-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 2007; 35:186-208. [PMID: 17846765 DOI: 10.1007/s00259-007-0560-9] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2007] [Accepted: 07/20/2007] [Indexed: 12/23/2022]
Abstract
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases controls critical pathways involved in epithelial cell differentiation, growth, division, and motility. Alterations and disruptions in the function of the HER-kinase axis can lead to malignancy. Many therapeutic agents targeting the HER-kinase axis are approved for clinical use or are in preclinical/clinical development. The ability to quantitatively image the HER-kinase axis in a noninvasive manner can aid in lesion detection, patient stratification, new drug development/validation, dose optimization, and treatment monitoring. This review summarizes the current status in multimodality imaging of the HER-kinase axis using PET, SPECT, optical, and MR imaging. The targeting ligands used include small-molecule tyrosine kinase inhibitors, peptides, proteins, antibodies, and engineered antibody fragments. EGFR and HER2 imaging have been well documented in the past, and imaging of HER3, HER4, HER heterodimers, and HER-kinase mutants deserves significant research effort in the future. Successful development of new HER-kinase-targeted imaging agents with optimal in vivo stability, targeting efficacy, and desirable pharmacokinetics for clinical translation will enable maximum benefit in cancer patient management.
Collapse
Affiliation(s)
- Weibo Cai
- The Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA.
| | | | | |
Collapse
|
14
|
Masi S, Top S, Boubekeur L, Jaouen G, Mundwiler S, Spingler B, Alberto R. Direct Synthesis of Tricarbonyl(cyclopentadienyl)rhenium and Tricarbonyl(cyclopentadienyl)technetium Units from Ferrocenyl Moieties− Preparation of 17α-Ethynylestradiol Derivatives Bearing a Tricarbonyl(cyclopentadienyl)technetium Group. Eur J Inorg Chem 2004. [DOI: 10.1002/ejic.200300731] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|